PDA001

Phase 2Biologic

CCelularity Incorporated

PDA001 is one of 58 biologic programs targeting Pulmonary Sarcoidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Pulmonary SarcoidosisPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Rituxan

Roche

Preclinical

61 3

Cimzia

UCB

Preclinical

30 4

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 5

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 6

Cataflam

Novartis

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

PDA001

CCelularity Incorporated

Phase 2

1 9

Valium

Akero Therapeutics

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Terminated·CCelularity Incorporated·Phase 2·NCT01261403·26 enrolled

Safety and Efficacy1 trial

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Completed·CCelularity Incorporated·Phase 1·NCT01769755·14 enrolled

Pulmonary Sarcoidosis1 trial

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

Terminated·CCelularity Incorporated·Phase 1·NCT01440192·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PDA001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PDA001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PDA001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celularity Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CCelularity Incorporated

PDA001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Safety and Efficacy1 trial

Pulmonary Sarcoidosis1 trial

References

Drug Info

Quick Facts

Related News